Hyperfractionated and accelerated radiotherapy in head and neck cancer: Results of the EORTC trials and impact on clinical practice;Radiotherapie hyperfractionnee et acceleree dans les cancers de la tete et du cou: Resultats des essais de l'EORTC et impact sur la pratique clinique

Bulletin du Cancer/Radiotherapie

Volumn 83, Issue 4, 1996, Pages 314-320

  Horiot, J C ^a,o   Bontemps, P ^b   Begg, A C ^c   Le Fur, R ^d   Van Den Bogaert, W ^e   Bolla, M ^f   N'Guyen, T ^g   Van Den Weijngaert, D ^h   Bernier, J ⁱ   Lusinchi, A ^j   Stuschke, D ^k   Lopez Torrecilla, D ^l   Jancar, B ^m   Collette, L ⁿ   Van Glabbeke, M ⁿ   Pierart, M ⁿ  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d CENTRE HENRI BECQUEREL   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f CHU La Tronche and University   (France)

^g INSTITUT JEAN GODINOT   (France)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ OSPEDALE SAN GIOVANNI   (Switzerland)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^m INSTITUTE OF ONCOLOGY   (Slovenia)

ⁿ EORTC DATA CENTER   (Belgium)

^o Service de Radiotherapie   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEAD AND NECK TUMOR; METHODOLOGY; MULTICENTER STUDY; OROPHARYNX TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RADIATION DOSE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; TIME;

ACTUARIAL ANALYSIS; CARCINOMA, SQUAMOUS CELL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TIME FACTORS;

EID: 0029801542     PISSN: 09244212     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-4212(97)86083-5     Document Type: Conference Paper

References (8)

1. 1 Begg AC, McNally NJ, Shrieve DC et al. Method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985;6:620-6
2. 2 Begg AC, Hofland I, Moonen L et al. The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys 1990;19: 1449-53
3. 3 Horiot JC, Nabid A, Chaplain G et al. Clinical experience with multiple fractions per day (MFD) in the radiotherapy of head and neck carcinoma. J Eur Radiother 1982;3:79-89
4. 4 Horiot JC, Van den Bogaert W, Ang KK et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. In: Vaeth JM, Meyer J, eds. Frontiers of radiation therapy and oncology. Karger Basel Publish, 1988:149-61
5. 5 Horiot JC, Le Fur R, NGuyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-41
6. 6 Van den Bogaert W, Van der Schueren E, Vantongelen C et al. Late results of multiple fractions per day (MFD) with Misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group. Radiother Oncol 1985;3:139-44
7. 7 Van den Bogaert W, Horiot JC, Van der Schueren E. Radiotherapy with multiple fractions per day. In: Steel GG, Adams GE, Horwich A, eds. The Biological basis of radiotherapy, 2nd edition. New York: Elsevier Publish, 1989:209-22
8. 8 Withers R, Horiot JC. Hyperfractionation. In: Withers R, Peters LJ, eds. Innovations in Radiation Oncology. Berlin: Springer Publish, 1987:223-30